Aurigene Pharmaceutical Services Limited’s Post

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> WuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim staff; Ron Renaud’s latest biotech; and more : Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Look out next week for our annual Women in Biopharma R&D report celebrating 20 exceptional researchers, entrepreneurs, data experts and more. We’ll kick off a related event on Tuesday at 11 am ET with a fireside chat with Marsha Henderson, the FDA’s former associate commissioner for women’s health, followed by a panel with two of this year’s honorees. You can register here. WuXi companies consider selling units impacted by Biosecure — report WuXi AppTec and WuXi Biologics are looking to sell part of their operations that have struggled because of the Biosecure Act, the Financial Times reported. WuXi AppTec said in a statement that it’s “assessing options for continuing WuXi Advanced Therapies’ operations in line with our priorities.” Endpoints News’ Jared Whitlock has the latest. Eli Lilly resolves tirzepatide shortage In other manufacturing news, the FDA confirmed on Wednesday that the shortage for Eli Lilly’s blockbuster weight loss and diabetes drug tirzepatide is resolved and Lilly can officially meet present demand. That may create confusion for patients relying on cheaper compounded versions, which are permitted in certain circumstances when a drug is in short supply. J&J, Bayer trim New Jersey staff Both Johnson & Johnson and Bayer revealed plans to lay off workers in New Jersey this week, with the moves expected to come before the end of December. J&J will lay off 231 employees while Bayer will lay off 57. Neither elaborated on which units would be affected, but Bayer’s comes amidst a broader, conglomerate-wide reorganization. Ron Renaud’s latest biotech Obesity biotechs continue to attract significant financing rounds, and longtime entrepreneur Ron Renaud is behind the latest company, Kailera Therapeutics. The company pulled in $400 million and partnered with Jiangsu Hengrui Pharmaceuticals on four programs. CEO Renaud expects a global Phase 3 to start “as quickly” as it can. Roche bets on Regor drugs In what analysts described as a “sensible bolt-on,” Roche spent $850 million in upfront cash to acquire two experimental CDK inhibitors from Regor Pharmaceuticals. The drugs are designed to treat breast and brain cancer, respectively. Roche will take over development after both programs advance through Phase 1 studies. Prime cuts pipeline, partners with BMS Gene editing companies have faced cutbacks this year, and now David Liu’s Prime Medicine is joining the fray. The startup,… #lucidquest #genetherapy #celltherapy

TerrayTherapeuticsAdvances #AIInPharma Terray Therapeutics has secured $120 million in funding to boost its AI-driven small-molecule drug development platform. Led by Bedford Ridge Capital and NVentures, this investment supports Terray's mission to revolutionize drug discovery using its AI model, tNova. The company boasts a vast chemistry dataset, significantly enhancing drug development success rates. Partnerships with Bristol Myers Squibb and Calico Life Sciences highlight Terray's industry influence. #TerrayTherapeutics #AIDrugDevelopment #Biotech #PharmaInnovation #Saasverse What role do you think AI will play in the future of drug development?

Earlier this week, Prof Alan Boyd had the pleasure of attending the 2-day Fierce Biotech Summit in Boston. A big thank you to the organizers at Fierce Pharma, and to the insightful speakers and panelists for leading some great discussions on the future of the biotech industry. 📧 If you didn't get the chance to connect with Alan at the Summit, or would like to learn more about how Boyds can support your path to drug approval, reach out at [email protected]. Fierce Life Sciences Events #FierceBiotechSummit #BiotechInnovation #FierceBiotech #Biotech2024

Gene&Cell Therapy >> WuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim staff; Ron Renaud’s latest biotech; and more : Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. Look out next week for our annual Women in Biopharma R&D report celebrating 20 exceptional researchers, entrepreneurs, data experts and more. We’ll kick off a related event on Tuesday at 11 am ET with a fireside chat with Marsha Henderson, the FDA’s former associate commissioner for women’s health, followed by a panel with two of this year’s honorees. You can register here. WuXi companies consider selling units impacted by Biosecure — report WuXi AppTec and WuXi Biologics are looking to sell part of their operations that have struggled because of the Biosecure Act, the Financial Times reported. WuXi AppTec said in a statement that it’s “assessing options for continuing WuXi Advanced Therapies’ operations in line with our priorities.” Endpoints News’ Jared Whitlock has the latest. Eli Lilly resolves tirzepatide shortage In other manufacturing news, the FDA confirmed on Wednesday that the shortage for Eli Lilly’s blockbuster weight loss and diabetes drug tirzepatide is resolved and Lilly can officially meet present demand. That may create confusion for patients relying on cheaper compounded versions, which are permitted in certain circumstances when a drug is in short supply. J&J, Bayer trim New Jersey staff Both Johnson & Johnson and Bayer revealed plans to lay off workers in New Jersey this week, with the moves expected to come before the end of December. J&J will lay off 231 employees while Bayer will lay off 57. Neither elaborated on which units would be affected, but Bayer’s comes amidst a broader, conglomerate-wide reorganization. Ron Renaud’s latest biotech Obesity biotechs continue to attract significant financing rounds, and longtime entrepreneur Ron Renaud is behind the latest company, Kailera Therapeutics. The company pulled in $400 million and partnered with Jiangsu Hengrui Pharmaceuticals on four programs. CEO Renaud expects a global Phase 3 to start “as quickly” as it can. Roche bets on Regor drugs In what analysts described as a “sensible bolt-on,” Roche spent $850 million in upfront cash to acquire two experimental CDK inhibitors from Regor Pharmaceuticals. The drugs are designed to treat breast and brain cancer, respectively. Roche will take over development after both programs advance through Phase 1 studies. Prime cuts pipeline, partners with BMS Gene editing companies have faced cutbacks this year, and now David Liu’s Prime Medicine is joining the fray. The startup, focused on “CRISPR 3.0” prime editing, slashed its… #lucidquest #genetherapy #celltherapy

We're excited to announce the strategic partnership between Vipergen, www.vipergen.com, with Aurigene Pharmaceutical Services ltd, https://lnkd.in/e9_X74y By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification. The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein. Access the full story here: https://lnkd.in/eANxvqeX Commenting on the partnership Akhil Ravi, CEO of Aurigene said that “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer centric approach. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us." Nils Jakob Vest Hansen, Ph.D., CEO of Vipergen, added that “we are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers. #collaboration #partnership #media #drugdiscovery #screening #DNA #encoded #library #innovation #CRDMO #aurigene  #Vipergen

"Thrilled to share that I recently attended the 55th SPSR Webinar on 'Multi-omics Approach: A Paradigm Shift in Drug Discovery'. It was an insightful session exploring the latest advancements in drug discovery through multi-omics approaches. Looking forward to applying these innovative techniques in my work. #SPSR #MultiOmics #DrugDiscovery

Zhinan Xia, CEO & Founder of @Abimmune Bio, presenting at Day 2 of the 7th Alcor Drug Discovery Platform! Join us as Zhinan introduces their cutting-edge Novel ADC platform, paving the way for transformative therapies. Don't miss out on this opportunity to explore the future of targeted drug delivery! #AlcorDrugDiscovery #ADCPlatform #Innovation #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Check out our posters illustrating the power of SPR to swiftly drive drug discovery programs forward and yield critical compound binding data! The ability to characterize an interaction can be critical for deciding how to progress a project. These posters demonstrate several of our capabilities at Charnwood Discovery: ➡ SPR assay development for difficult targets ➡ Small molecule screening in multiple different assay formats ➡ Integrated drug discovery between different disciplines and departments #spr #assaydevelopment #drugdiscovery

🆕 🤖 💊 𝐀𝐈 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐒𝐞𝐜𝐭𝐨𝐫 𝐊𝐞𝐞𝐩𝐬 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐧𝐠 The #AI in the #drugdiscovery and development race has been going for more than a decade now, and today we see all signs of the sector’s consolidation.  Over the last 6 years, there were more than 30 M&As events in this space. According to the BioPharmaTrend.com report some of the AI-focused deals in drug discovery, #biotech, and #clinicaltrials space included: the 2018 acquisition of Flatiron Health by Roche for $1.9 billion; the 2019 acquisition of Numerate by Valo Health; the 2020 acquisition of Haystack Biosciences by insitro the 2021 acquisition of Prescient Design by Genentech; the 2022 acquisitions of Zymergen by Ginkgo Bioworks, Inc. for $300 million; the 2023 acquisition of InstaDeep by BioNTech SE for $549 million and double acquisition of Cyclica and Valence Labs by Recursion Pharmaceuticals for around $90 million combined -- to name just a few.  Some of the notable deals are summarized in the figure below: Read more: https://lnkd.in/dPSj-XDi

What's the most impactful or misleading advice you've encountered in your career? Join us for this Pharma's Almanac roundtable, where a panel of industry experts delve into the conventional wisdom they believe is outdated, misguided, or simply incorrect. Read the full roundtable here: https://lnkd.in/eTsQ4qj9 Our roundtable features contributors from Vectron Biosolutions AS, Alconox Inc., PPD, Dynamk Capital, Mikart, LLC, Tanvex CDMO, Scorpius BioManufacturing, Inc., Envisagenics, Qualtrics, Astrea Bioseparations, Charles River Laboratories, Epocrates Inc, eClinical Solutions, Rentschler Biopharma, Be The Match BioTherapies, MMIT (Managed Markets Insight & Technology), Catalent Pharma Solutions, LabVantage Solutions, Inc, Personalis, Inc., Rune Labs, Mission Bio, VintaBio, BioCina, Center for Breakthrough Medicines, Alto Neuroscience, Elixirgen Therapeutics, Inc., Seer, Karius, Opentrons Labworks Inc., Rani Therapeutics, OM1, Inc., BIOSENIC S.A., eXmoor Pharma, BioBridge Global, Terumo Blood and Cell Technologies, TrakCel, ScaleReady, Ori Biotech... (cont) #Biopharma #Insights #Pharma #Roundtable